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Purpose. We hypothesize that growth hormone (GH) plays a significant role in the regulation of the meibomian gland. To test our
hypothesis, we examined the influence of GH on mouse meibomian gland structure. Methods. We studied four groups of mice,
including (1) bovine (b) GH transgenic mice with excess GH; (2) GH receptor (R) antagonist (A) transgenic mice with decreased
GH; (3) GHR knockout (−/−) mice with no GH activity; and (4) wild type (WT) control mice. After mouse sacrifice, eyelids were
processed for morphological and image analyses. Results. Our results show striking structural changes in the GH-deficient animals.
Many of the GHR−/− and GHAmeibomian glands featured hyperkeratinized and thickened ducts, acini inserting into duct walls,
and poorly differentiated acini. In contrast, the morphology of WT and bGH meibomian glands appeared similar. The sizes of
meibomian glands of bGH mice were significantly larger and those of GHA and GHR−/− mice were significantly smaller than
glands of WTmice. Conclusions. Our findings support our hypothesis that the GH/IGF-1 axis plays a significant role in the control
of the meibomian gland. In addition, our data show that GH modulates the morphology and size of this tissue.
1. Introduction
Meibomian glands play a critical role in the health and well-
being of the eye. These tissues, which are relatively large
sebaceous glands, secrete a lipid mixture (i.e., meibum) that
promotes clear optical surface for the cornea, interferes with
bacterial colonization, and retards tear overflow [1–4]. These
secretions also enhance the stability and prevent the evapo-
ration of the tear film [1, 3, 5]. Conversely, meibomian gland
dysfunction (MGD) and the resulting meibum insufficiency
destabilize the tear film, increase its evaporation and osmolar-
ity, and are the most common cause of dry eye disease (DED)
[1, 6–10], which afflicts 40 million Americans [11]. In fact, a
recent study found that 86% of qualified DED patients show
signs of MGD [12].
The pathophysiology of human MGD has been linked
to several risk factors, especially aging [1, 13]. However, the
molecular mechanisms that underlie the impact of these
risk factors and the etiology of human MGD are largely
unknown.This lack of information, in turn, has hampered the
generation of safe and effective therapies for the treatment of
MGD.There is no cure for MGD.
We hypothesize that identification of factors that control
the physiology and pathophysiology of the meibomian gland
will permit the development of new treatments for MGD.We
further hypothesize that the growth hormone (GH)/insulin-
like growth factor 1 (IGF-1) axis is such a factor. GH is a pitu-
itary hormone that acts on multiple tissues to promote their
function ultimately resulting in growth. Notably, GH induces
the expression of IGF-1, whichmediatesmanyGH actions via
endocrine, paracrine, and autocrine pathways [14]. Together,
the GH/IGF-1 axis is a primary driving force of mammalian
growth and a conserved regulator of aging inmultiple species
[15].
In support of our hypothesis, we have discovered that
IGF-1 activates the PI3K/AKT and forkhead box O1 sig-
naling pathways, stimulates the proliferation, increases the
expression of sterol regulatory element-binding protein, and
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promotes lipid accumulation in human meibomian gland
epithelial cells [16, 17]. Moreover, we have discovered that
an antibody to the IGF-1 receptor, figitumumab, blocks the
IGF-1-induced cellular signaling and lipid accumulation [16],
which may account for this anticancer drug’s induction of
DED [18].
To continue to test our hypotheses, we sought in the
present study to determine the effect of GH on mouse
meibomian gland morphology and structure.
2. Materials and Methods
2.1. Mice. Weutilized four groups of mice, including (a) male
bovine (b) GH transgenic mice (bGH; 3.5 months of age)
with excess GH and IGF-1 signaling, which are a model of
acromegaly; (b) male GH receptor (R) gene knockout (−/−)
mice (GHR−/−; 2.7months of age) with noGH and low levels
of IGF-1, which are a model of Laron Syndrome; (c) male
and female GHR antagonist (A) transgenic mice (GHA; 5-6
months) with decreased GH and IGF-1 signaling, which are a
model of GH deficiency; and (d) age- and sex-matched wild
type (WT) littermate control mice in the same background
strain (C57BL/6J) as the other three groups [19, 20]. The
phenotypes of these mouse models have been extensively
characterized, including their body size, body composition,
glucose metabolism, and lifespan [21–28]. In brief, bGH
mice are very large, lean, and insulin-resistant and have a
shortened lifespan. In contrast, GHA and GHR−/− mice are
dwarf and obese, and the GHR−/−mice are extremely insulin
sensitive and live significantly longer than their littermate
controls [21–28]. All three mouse lines used were developed
at Ohio University and all animal procedures were approved
by the Institutional Animal Care and Use Committee of
Ohio University (Athens, OH). Following sacrifice by CO
2
inhalation, mouse heads were removed, fixed in 10% neutral
buffered formalin, stored at 4∘C overnight, wrapped, and
shipped on wet ice to the Schepens Eye Research Institute
(Boston,MA).After arrival, upper and lower eyelids, attached
to the globe, were removed as an entire unit and processed for
morphological and image analyses.
2.2. Histology. Eyelids were dehydrated in a series of graded
ethyl alcohols, then infiltrated, and embedded in glycol
methacrylate resin (Technovit 7100, Electron Microscopy
Sciences, Hatfield, PA, USA). Tissue samples were cut cross-
sectionally in a Historange microtome (LKB Bromma, Ger-
many) and sections (3 𝜇M) were placed onto glass slides.
Each eyelid was cut at 5 to 8 different locations (3 to 5
sections/location), and each locationwas separated by at least
200𝜇M. Sections were stained with Gill’s #2 hematoxylin and
eosin-y (Fisher Scientific, Pittsburgh, PA, USA) and overlaid
with mounting media and glass coverslips.
2.3. Meibomian Gland Analyses. Tissue sections were eval-
uated with a Nikon eclipse E800 microscope (Micro Video
Instruments, Inc., Avon, MA) at 100x and 400x magnifica-
tion. The section in each tissue location containing the most
clearly defined meibomian glands was imaged (𝑛 = 5 to 8
images/section/location). Visualizedmeibomian glands were
outlined manually and enclosed areas were quantified with
ImageJ (http://rsb.info.nih.gov/ij/).The area values were used
to represent the size of the meibomian glands in upper and
lower lids. One-tailed, unpaired t-test or two-way ANOVA
statistics were performed with GraphPad Prism 5 (La Jolla,
CA) to determine the significance (𝑝 < 0.05) of size differ-
ences between groups. The eyelid removal and histological
examinations were conducted in a “blinded” manner, such
that neither the sex nor the genotype of the samplewas known
by the investigator.
3. Results
Our histological analyses demonstrate that the morphology
of WT and bGH meibomian glands appear similar. In
contrast, there aremarkedmorphological changes in theGH-
deficient animals. Many of the GHR−/− and GHA meibo-
mian glands possessed hyperkeratinized and thickened ducts,
ducts containing cornifiedmaterials, secretory acini inserting
into duct walls, and poorly differentiated acini (Figure 1).
Image analyses showed that the sizes (i.e., area measure-
ments) of bGH mouse meibomian glands were significantly
larger than those of WT mice (Figure 2). The mean increase
in size wasmore than 2-fold for both upper and lower lidmei-
bomian glands (Figure 2). GHR−/−mice, on the other hand,
had significantly smaller meibomian glands (Figure 3), with
mean sizes 36% and 41% of the WT controls for upper and
lower lids, respectively (Figure 5).TheGHAmice also showed
significantly smaller meibomian glands in both upper and
lower lids (Figures 4(a), 4(b), 4(c), and 4(d)).Themeibomian
gland sizes of GHA mice relative to WT controls were both
58% for upper and lower lids (Figure 5). Interestingly, we also
detected a significant size difference betweenmale and female
WT mice in the upper lid (𝑝 = 0.04), which was not present
between male and female GHA mice (Figures 4(e) and 4(f)).
4. Discussion
Our findings demonstrate that decreased and/or disrupted
GH action is associated with striking alterations in the
morphology of mouse meibomian glands. The GHR−/−
and GHA glands contained hyperkeratinized and thickened
ducts, secretory acini inserting into duct walls, and poorly
differentiated acini. The meibomian gland sizes (i.e., area
measurements) of GHA and GHR−/−mice were also signif-
icantly smaller than those of age- and sex-matched WT con-
trols. In contrast, meibomian gland sizes of bGH mice were
significantly larger than those of WT mice, but the glandular
morphology of bGHand littermate controls appeared similar.
Our results support our hypothesis that the GH/IGF-1 axis
plays a significant role in the control of the meibomian gland.
More specifically, our data show that GH modulates the size
of this tissue and that GH insufficiency leads to striking
morphological changes.
Our discovery that GH regulates the meibomian gland
was not unexpected. GH is known to play an important role
in the growth of sebaceous glands elsewhere in the body
[29]. Sebaceous glands express GH receptors and GH has
been shown to directly induce the differentiation of sebaceous
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Figure 1: Meibomian gland morphology in male WT, GHA, and GHR−/− mice. (a) is from a WT mouse. (b) and (c) are from GHA mice.
(d) is from GHR−/− mice. In (b) and (d), the arrows point to the cornified materials in the ducts. In (c) and (d), the thick arrows point to
the secretory acini inserting into duct walls. In (d), the circle indicates possible gland dropout. All slides were stained with H & E, and the
magnifications are 400x. The size bar in (a) is 50 𝜇m in length.
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Figure 2: Meibomian gland morphology and size (i.e., area measurement) in male bGH and WT control mice. (a) and (c) H & E staining
in the upper and lower lid tissue showing meibomian glands. (b) and (d) quantification of upper and lower lid meibomian gland size. Each
data point represents the size of one meibomian gland, the horizontal bar represents the mean, and the error bar represents standard error of
the mean (SEM). Data were pooled from𝑁 = 5mice in each group. The magnifications for all photographs are 100x, and the size bar in (a)
is 500 𝜇m in length.
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Figure 3: Meibomian glandmorphology and size (i.e., area measurement) in male GHR−/− andWT control mice. (a) and (c) H & E staining
in the upper and lower lid tissue showing meibomian glands. (b) and (d) quantification of upper and lower lid meibomian gland size. Each
data point represents the size of one meibomian gland, the horizontal bar represents the mean, and the error bar represents SEM. Data were
pooled from𝑁 = 3mice in each group. The magnifications for all photographs are 100x, and the size bar in (a) is 500 𝜇m in length.
gland epithelial cells [30]. In addition, GH excess—as in
acromegaly—has been linked to increased sebum production
[31, 32], and GH insufficiency may lead to decreased seba-
ceous gland size and function [30, 33].
The morphological alterations associated with GH defi-
ciency and resistance appear to be very clinically relevant for
the eye.These changes, and in particular the hyperkeratinized
ducts and meibocyte integration into the duct wall, are
very similar to those observed in patients with obstructive
MGD [1]. Indeed, ductal hyperkeratinization is a prominent
characteristic of this disorder in humans [1]. Given that GH
levels decline with aging, this decrease may contribute to the
development of age-related MGD [1, 13].
The decreased size of meibomian glands in GHR−/−
mice and GHA mice represents another characteristic of
MGD, which often involves glandular atrophy and dropout
[1]. Such a size decline is consistent with the finding of
others [34–36], who reported reduced growth of orbital
structures in decreased GH action (e.g., Laron Syndrome).
In contrast, the larger size of meibomian glands in bGH
mice is analogous to the observation that the acromegalic
patients tend to have bigger sebaceous glands than normal
people [37]. It will be of particular interest in the future to
use volumetric techniques, such as meibography or three
dimensional reconstruction [38], to determine whether the
meibomian volumes in these mouse models reflect the area
measurement differences found in this study.
Our observation that female WT mice have larger upper
lid meibomian gland than the male WT mice is intriguing.
We have previously found that sex differences exist in the
morphology of the mouse meibomian gland and that these
may be due to the influence of estrogen and progesterone
[39]. It is possible that sexual dimorphism in glandular size
may be attributed, at least in part, to the known ability of sex
steroids to promote anabolic effects ofGH [40, 41].Thismight
account for why sex-related differences were not observed in
the meibomian glands of GHA mice. It is unclear why sex-
associated variations were not discovered in the size of lower
lid meibomian glands. There are many structural differences
between the glands of the upper and lower lids [1], and these
could theoretically extend to functional variations as well.
In conclusion, our results support our hypothesis that the
GH/IGF-1 axis plays a significant role in the regulation of the
meibomian gland.Our findings also suggest that theGHR−/−
Journal of Ophthalmology 5
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Figure 4: Meibomian gland morphology and size (i.e., area measurement) in both male and female GHA and WT control mice. (a) and (c)
H & E staining in the upper and lower lid tissue showing meibomian glands. (b) and (d) quantification of upper and lower lid meibomian
gland size without distinguishing sexes. (e) and (f) quantification of upper and lower lid meibomian gland size of both sexes. Each data point
represents the size of one meibomian gland, the horizontal bar represents the mean, and the error bar represents SEM. Data were pooled
from𝑁 = 5mice in each group. The magnifications for all photographs are 100x, and the size bar in (a) is 500 𝜇m in length.
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Figure 5: The ratio of average meibomian gland size relative to WT controls in GHR−/−, GHA, and bGHmice for both upper (a) and lower
(b) eyelids. TheWT in each group was set to 1. For the GHA group, the data for both sexes were pooled. Data shown are mean ratios ± SEM.
mice andGHAmicemay serve as anMGDanimalmodel, and
the GH/IGF-1 axis may become a new target for the potential
treatment of MGD.
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